Close menu




December 1st, 2020 | 10:23 CET

BP, Triumph Gold, K+S - who offers the best trading opportunities?

  • Investments
Photo credits: pixabay.com

The asset class "commodities" offers investors a broad and exciting investment universe. Especially the high cyclicality of commodity prices provides opportunities. When Gold & Co is in fashion, stocks that operate in this field often develop explosively. But also, commodities that are not among the favorites of investors at times, or are subject to strong fluctuations, such as oil & gas or potash, offer good (countercyclical) investment and trading opportunities.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: CA8968121043 , GB0007980591 , DE000KSAG888

Table of contents:


    BP PLC - 30% price increase in the last weeks, use volatility for trading

    The price of oil has gone off the rails this year. The supply and demand situation is difficult to assess given the fear of recession and the power games of significant players. The volatility was partly absurd.

    It is therefore hardly surprising that large oil companies are among the worst money destroyers in 2020. The share price charts were correspondingly positive. In recent weeks, however, the sentiment of the oil industry has also improved in the course of the generally good stock market phase. The BP share gained 30% last month. The payment of a dividend and even the continued adherence to payouts may seem like a marginal note, but it is not, given the disastrous figures. All because BP is demonstrating financial strength and sending a clear signal that it can successfully adapt structures and costs through a transformation process.

    In the first nine months of the financial year, the industry heavyweight posted a loss of no less than USD 21.7 billion, compared with a profit of USD 4 billion a year earlier. But the worst is probably behind the shareholders because the terrible loss stems mainly from Q2. The third quarter was "only" in the red with USD 450 million. Nevertheless, it may be too early to give the all-clear. For the disagreement within the oil network, Opec+ over an extension of production cuts is causing dark clouds to gather again. No reason for bad mood though - volatile stock market phases are full of trading opportunities.

    TRIUMPH GOLD CORP - bet on the further rise of gold and copper

    Gold is the best-known crisis currency. We have seen this impressively in recent months. Even though the price of the precious metal has recently fallen, experts agree that the price can only rise in the medium term. For a completely different reason, the industrial metal, copper, has developed strongly this year. The forecast demand in the wake of electromobility suggests that the gap between supply and demand will diverge significantly in the future. It is certainly not a bad idea to position oneself in the two raw materials.

    With shares in Triumph Gold, investors can do just that. Triumph Gold Corp is a mineral exploration Company currently focused on its 100% owned Freegold Mountain project in the Yukon. The property is located in the gold-copper belt of the Dawson Range, where the Casino copper deposit, the Coffee gold deposit and the Klaza gold prospect, are also located.

    The Vancouver-based Company currently has a market capitalization of CAD 25 million. The stock has lost approximately 50% over the summer and now offers an attractive level for (post) purchases.

    K+S AG - Commerzbank sees further price potential of 30%

    In recent weeks, the price of the K+S share has experienced a rollercoaster ride. After a long dry spell, the share finally appeared to be heading for liberation in mid-October with the announcement that it intended to sell its salt business in North and South America. However, the share price quickly retreated from the price level of over EUR 7 and corrected to EUR 5.66.

    Today, the share is 2 euros higher again. What are the reasons? Several analysts have now issued price targets of over EUR 7. Commerzbank stood out particularly positively last Friday. The Coba analyst upgraded K+S from "hold" to "buy" and increased the target price from EUR 7 to EUR 10! The expert cited as reasons, the unexpectedly high proceeds expected from the sale of the American salt business, a significant reduction in balance sheet risks after write-downs, and a positive outlook.

    As already mentioned, volatility offers trading opportunities.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read